2Geisler JP, Geisler HE,Manahan KJ, et al. Nuclear andcytop lasmic c2myc staining in endometrial carcinoma and their relation ship to survival [J]. Int J Gynecol Cancer,2004, 14:133-137.
4Santin AD, Bellone S, Van Stedum S, et al. Amplification of c- erbB-2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma[J]. Cancer, 2005, 104(7):1391-1397.
5Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an indepen dent prognostic factor in endometrial cancer: association without come in a large cohort of surgically staged patients[J]. J Clin On col, 2006, 24(15):2376-2385.
3Bartosch C,Manuel Lopes J,Oliva E.Endometrial carcinomas:a review emphasizing overlapping and distinctive morphological and immunohistochemical features[J].Adv Anat Pathol,2011,18(6):415-437.
4Termine JD, Kleinman HK,Whitson SW, et al.Osteonectin,a bone- specific protein linking mineral to collagen[J].Cell,1981,26(1Ptl): 99-105.
5Tai IT,Tang MJ.SPARC in cancer biology:its role in cancer progression and potential for therapy[J].Drug Resist Updat,2008, 11(6):231-246.
6Guldi AJ,Abu JG,Tognazzi K,et al.Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma[J].Cancer,1996,78(3):454-460.
7Abulafis O,Triest WE,Sherer DM.Angiogenesis in malignancies of the female genital tract[J].Gynecol Onco1,1999,72(2):220-230.
8Chlenski A,Liu S,Guerrero LJ,et al.SPARC expression is associated with impaired tumor growth,inhibited angiogenesis and changes in the extracellular matrix[J].Int J Cancer,2006,118(2):310-316.
9Yunker CK,Golembieski W, Lemke N,et al.SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion[J].Int J Cancer,2008,122(12):2735-2743.
10Yoshida Y, Kurokawa T, Horiuchi Y, et al. Localisation of phosphorylated roTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer. European Journal of Cancer,2010,46:3445-3452.
